This report aims to provide a comprehensive presentation of the global market for VEGF & VEGFR Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGF & VEGFR Inhibitor Drugs. This report contains market size and forecasts of VEGF & VEGFR Inhibitor Drugs in global, including the following market information:
Global VEGF & VEGFR Inhibitor Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global VEGF & VEGFR Inhibitor Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tyrosine Kinase Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of VEGF & VEGFR Inhibitor Drugs include Pfizer, Novartis AG, GlaxoSmithKline plc, Sanofi, AstraZeneca plc, Bristol-Myers-Squibb Company, Genentech, Inc. (Roche), Merck & Co., Inc. and Bayer AG, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the VEGF & VEGFR Inhibitor Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global VEGF & VEGFR Inhibitor Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global VEGF & VEGFR Inhibitor Drugs Market Segment Percentages, by Type, 2022 (%)
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Global VEGF & VEGFR Inhibitor Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global VEGF & VEGFR Inhibitor Drugs Market Segment Percentages, by Application, 2022 (%)
Oncology
Ophthalmology
Others
Global VEGF & VEGFR Inhibitor Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global VEGF & VEGFR Inhibitor Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies VEGF & VEGFR Inhibitor Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies VEGF & VEGFR Inhibitor Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis AG
GlaxoSmithKline plc
Sanofi
AstraZeneca plc
Bristol-Myers-Squibb Company
Genentech, Inc. (Roche)
Merck & Co., Inc.
Bayer AG
Eli Lilly & Company
Outline of Major Chapters:
Chapter 1: Introduces the definition of VEGF & VEGFR Inhibitor Drugs, market overview.
Chapter 2: Global VEGF & VEGFR Inhibitor Drugs market size in revenue.
Chapter 3: Detailed analysis of VEGF & VEGFR Inhibitor Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of VEGF & VEGFR Inhibitor Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 VEGF & VEGFR Inhibitor Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global VEGF & VEGFR Inhibitor Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global VEGF & VEGFR Inhibitor Drugs Overall Market Size
2.1 Global VEGF & VEGFR Inhibitor Drugs Market Size: 2022 VS 2029
2.2 Global VEGF & VEGFR Inhibitor Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top VEGF & VEGFR Inhibitor Drugs Players in Global Market
3.2 Top Global VEGF & VEGFR Inhibitor Drugs Companies Ranked by Revenue
3.3 Global VEGF & VEGFR Inhibitor Drugs Revenue by Companies
3.4 Top 3 and Top 5 VEGF & VEGFR Inhibitor Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies VEGF & VEGFR Inhibitor Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 VEGF & VEGFR Inhibitor Drugs Players in Global Market
3.6.1 List of Global Tier 1 VEGF & VEGFR Inhibitor Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 VEGF & VEGFR Inhibitor Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global VEGF & VEGFR Inhibitor Drugs Market Size Markets, 2022 & 2029
4.1.2 Tyrosine Kinase Inhibitors
4.1.3 Monoclonal Antibodies
4.1.4 Others
4.2 By Type - Global VEGF & VEGFR Inhibitor Drugs Revenue & Forecasts
4.2.1 By Type - Global VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2023
4.2.2 By Type - Global VEGF & VEGFR Inhibitor Drugs Revenue, 2024-2029
4.2.3 By Type - Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global VEGF & VEGFR Inhibitor Drugs Market Size, 2022 & 2029
5.1.2 Oncology
5.1.3 Ophthalmology
5.1.4 Others
5.2 By Application - Global VEGF & VEGFR Inhibitor Drugs Revenue & Forecasts
5.2.1 By Application - Global VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2023
5.2.2 By Application - Global VEGF & VEGFR Inhibitor Drugs Revenue, 2024-2029
5.2.3 By Application - Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global VEGF & VEGFR Inhibitor Drugs Market Size, 2022 & 2029
6.2 By Region - Global VEGF & VEGFR Inhibitor Drugs Revenue & Forecasts
6.2.1 By Region - Global VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2023
6.2.2 By Region - Global VEGF & VEGFR Inhibitor Drugs Revenue, 2024-2029
6.2.3 By Region - Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2029
6.3.2 US VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.3.3 Canada VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.3.4 Mexico VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2029
6.4.2 Germany VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.4.3 France VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.4.4 U.K. VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.4.5 Italy VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.4.6 Russia VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.4.7 Nordic Countries VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.4.8 Benelux VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2029
6.5.2 China VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.5.3 Japan VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.5.4 South Korea VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.5.5 Southeast Asia VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.5.6 India VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2029
6.6.2 Brazil VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.6.3 Argentina VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2029
6.7.2 Turkey VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.7.3 Israel VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
6.7.5 UAE VEGF & VEGFR Inhibitor Drugs Market Size, 2018-2029
7 VEGF & VEGFR Inhibitor Drugs Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.1.4 Pfizer VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Novartis AG
7.2.1 Novartis AG Company Summary
7.2.2 Novartis AG Business Overview
7.2.3 Novartis AG VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.2.4 Novartis AG VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.2.5 Novartis AG Key News & Latest Developments
7.3 GlaxoSmithKline plc
7.3.1 GlaxoSmithKline plc Company Summary
7.3.2 GlaxoSmithKline plc Business Overview
7.3.3 GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.3.4 GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.3.5 GlaxoSmithKline plc Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Company Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.4.4 Sanofi VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.4.5 Sanofi Key News & Latest Developments
7.5 AstraZeneca plc
7.5.1 AstraZeneca plc Company Summary
7.5.2 AstraZeneca plc Business Overview
7.5.3 AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.5.4 AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.5.5 AstraZeneca plc Key News & Latest Developments
7.6 Bristol-Myers-Squibb Company
7.6.1 Bristol-Myers-Squibb Company Company Summary
7.6.2 Bristol-Myers-Squibb Company Business Overview
7.6.3 Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.6.4 Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers-Squibb Company Key News & Latest Developments
7.7 Genentech, Inc. (Roche)
7.7.1 Genentech, Inc. (Roche) Company Summary
7.7.2 Genentech, Inc. (Roche) Business Overview
7.7.3 Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.7.4 Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.7.5 Genentech, Inc. (Roche) Key News & Latest Developments
7.8 Merck & Co., Inc.
7.8.1 Merck & Co., Inc. Company Summary
7.8.2 Merck & Co., Inc. Business Overview
7.8.3 Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.8.4 Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.8.5 Merck & Co., Inc. Key News & Latest Developments
7.9 Bayer AG
7.9.1 Bayer AG Company Summary
7.9.2 Bayer AG Business Overview
7.9.3 Bayer AG VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.9.4 Bayer AG VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.9.5 Bayer AG Key News & Latest Developments
7.10 Eli Lilly & Company
7.10.1 Eli Lilly & Company Company Summary
7.10.2 Eli Lilly & Company Business Overview
7.10.3 Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Major Product Offerings
7.10.4 Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Revenue in Global Market (2018-2023)
7.10.5 Eli Lilly & Company Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. VEGF & VEGFR Inhibitor Drugs Market Opportunities & Trends in Global Market
Table 2. VEGF & VEGFR Inhibitor Drugs Market Drivers in Global Market
Table 3. VEGF & VEGFR Inhibitor Drugs Market Restraints in Global Market
Table 4. Key Players of VEGF & VEGFR Inhibitor Drugs in Global Market
Table 5. Top VEGF & VEGFR Inhibitor Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global VEGF & VEGFR Inhibitor Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global VEGF & VEGFR Inhibitor Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies VEGF & VEGFR Inhibitor Drugs Product Type
Table 9. List of Global Tier 1 VEGF & VEGFR Inhibitor Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 VEGF & VEGFR Inhibitor Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - VEGF & VEGFR Inhibitor Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - VEGF & VEGFR Inhibitor Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - VEGF & VEGFR Inhibitor Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - VEGF & VEGFR Inhibitor Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 32. Pfizer VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Novartis AG Company Summary
Table 35. Novartis AG VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 36. Novartis AG VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Novartis AG Key News & Latest Developments
Table 38. GlaxoSmithKline plc Company Summary
Table 39. GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 40. GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. GlaxoSmithKline plc Key News & Latest Developments
Table 42. Sanofi Company Summary
Table 43. Sanofi VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 44. Sanofi VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Sanofi Key News & Latest Developments
Table 46. AstraZeneca plc Company Summary
Table 47. AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 48. AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. AstraZeneca plc Key News & Latest Developments
Table 50. Bristol-Myers-Squibb Company Company Summary
Table 51. Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 52. Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Bristol-Myers-Squibb Company Key News & Latest Developments
Table 54. Genentech, Inc. (Roche) Company Summary
Table 55. Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 56. Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Genentech, Inc. (Roche) Key News & Latest Developments
Table 58. Merck & Co., Inc. Company Summary
Table 59. Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 60. Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Merck & Co., Inc. Key News & Latest Developments
Table 62. Bayer AG Company Summary
Table 63. Bayer AG VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 64. Bayer AG VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Bayer AG Key News & Latest Developments
Table 66. Eli Lilly & Company Company Summary
Table 67. Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Product Offerings
Table 68. Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Eli Lilly & Company Key News & Latest Developments
List of Figures
Figure 1. VEGF & VEGFR Inhibitor Drugs Segment by Type in 2022
Figure 2. VEGF & VEGFR Inhibitor Drugs Segment by Application in 2022
Figure 3. Global VEGF & VEGFR Inhibitor Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global VEGF & VEGFR Inhibitor Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global VEGF & VEGFR Inhibitor Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by VEGF & VEGFR Inhibitor Drugs Revenue in 2022
Figure 8. By Type - Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 16. US VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 20. Germany VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 28. China VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa VEGF & VEGFR Inhibitor Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE VEGF & VEGFR Inhibitor Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novartis AG VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. GlaxoSmithKline plc VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Sanofi VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. AstraZeneca plc VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bristol-Myers-Squibb Company VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Genentech, Inc. (Roche) VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Merck & Co., Inc. VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Bayer AG VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Eli Lilly & Company VEGF & VEGFR Inhibitor Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
